ZYBT
NASDAQ · Pharmaceuticals
Zhengye Biotechnology Holdin
$0.83
-0.04 (-4.43%)
Financial Highlights (FY 2026)
Revenue
142.12M
Net Income
8.63M
Gross Margin
49.0%
Profit Margin
6.1%
Rev Growth
+854.8%
D/E Ratio
0.30
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 49.0% | 66.6% | 66.6% | 66.6% |
| Operating Margin | 8.8% | 21.8% | 23.4% | 26.6% |
| Profit Margin | 6.1% | 22.3% | 18.0% | 17.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 142.12M | 12.11M | 10.68M | 11.04M |
| Gross Profit | 69.62M | 8.07M | 7.12M | 7.36M |
| Operating Income | 12.53M | 2.63M | 2.49M | 2.94M |
| Net Income | 8.63M | 2.69M | 1.92M | 1.97M |
| Gross Margin | 49.0% | 66.6% | 66.6% | 66.6% |
| Operating Margin | 8.8% | 21.8% | 23.4% | 26.6% |
| Profit Margin | 6.1% | 22.3% | 18.0% | 17.9% |
| Rev Growth | +854.8% | -0.1% | -5.4% | +15.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.90M | 9.50M | 11.04M | 9.33M |
| Total Equity | 12.82M | 25.46M | 25.42M | 24.63M |
| D/E Ratio | 0.30 | 0.37 | 0.43 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 31.79M | 3.66M | 3.67M | 3.48M |
| Free Cash Flow | — | 1.61M | 1.47M | 1.80M |